SCHEMBL24091986

SCHEMBL24091986

CCc1ccc2nc(N)c(C#N)cc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.57
ALDH1A1 P00352 4/20 0.57
GAA P10253 3/20 0.57
TSHR P16473 2/20 0.56
CASP1 P29466 1/20 0.56
LMNA P02545 3/20 0.51
NPSR1 Q6W5P4 3/20 0.51
MAPT P10636 4/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
MAPK1 P28482 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 2/20 0.47
HPGD P15428 1/20 0.47
PTK2B Q14289 1/20 0.47
PKM P14618 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL807478 0.79 KDM4E (0.62) KDM4EALDH1A1GAATSHRCASP1
SCHEMBL25955722 0.77 KMT2A (0.51) KDM4EALDH1A1GAATSHRCASP1
SCHEMBL22521434 0.76 SMN1; SMN2 (0.50) KDM4EALDH1A1GAATSHRCASP1
SCHEMBL22521421 0.76 KMT2A (0.50) KDM4EALDH1A1GAATSHRCASP1
SCHEMBL789748 0.76 KDM4E (0.62) KDM4EALDH1A1GAANPSR1MAPT
SCHEMBL789995 0.76 KDM4E (0.62) KDM4EALDH1A1GAALMNANPSR1
SCHEMBL22521377 0.75 KDM4E (0.57) KDM4EALDH1A1GAATSHRNPSR1
SCHEMBL31751233 0.73 KDM4E (0.58) KDM4EALDH1A1GAACASP1MAPK1
SCHEMBL941858 0.73 ALDH1A1 (1.00) KDM4EALDH1A1GAATSHRLMNA
SCHEMBL29904585 0.73 ALDH1A1 (1.00) KDM4EALDH1A1GAATSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11198699-B2 Compounds targeting PRMT5 ALIGOS THERAPEUTICS, INC. (US) 2021-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11198699-B2 Compounds targeting PRMT5 PRMT5, PRMT1, PRMT6 KDM4E 47/4885ALDH1A1 3913/4885GAA 2900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.